From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2023 call → NO我们只需要根据提供的文本回答是或否。关键问题是管理层是否描述了公司最近从需要说服的候选者转变为在买家采购系统中被批准、指定、列出、合格、注册、报销或预先授权的选择,从而无需每次单独销售即可获得业务,并且这种状态是新的,大部分量尚未反映在结果中。 扫描文本:管理层讨论了各种基金、平台、合作伙伴关系。他们提到了CAIS投资、iCapital、TIFIN等。他们谈到了“Evergreen平台”和零售渠道。他们提到了“战略技术投资”和“合作伙伴关系”。但有没有具体提到被列入批准供应商名单、处方集、网络等?他们谈到了“渠道渗透”和“关系”。他们提到“我们的最新二级基金已经看到来自零售投资者的承诺超过1.45亿美元,占基金迄今筹集资本的近14%”。这似乎是通过分销渠道的销售,而不是被列入系统。 他们提到了“CAIS”作为“技术支持的另类投资开放市场”,但这是投资,而不是被列入。他们谈到了“利用基础设施和信任”,但这是关于分销,而不是被列入采购系统。 没有明确提到公司被添加到批准名单、处方集、网络等。他们谈论的是销售努力和分销关系。没有提到“预先授权”或“报销”或“指定”等。 此外,他们提到“我们继续扩大渠道渗透”,但这是持续的努力,而不是新的状态。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.